Table 2. Demographic and clinical features of enrolled subjects.
| PSP (51) | PD (28) | HC (30) | p | |
|---|---|---|---|---|
| Age, years | 71.00 (10.0) | 67.00 (8.0) | 66.00 (13.5) | 0.229 |
| Disease duration, years | 4.00 (4.00) | 5.00 (6.0) | NA | 0.271 |
| Sex, men, n (%) | 29 (56.9) | 21 (75) | 11 (36.7) | 0.013 |
| Education, years | 9.00 (9.0) | 11.5 (8) | 8.00 (10.5) | 0.347 |
| MMSE | 24.00 (6.0) | 28.00 (3.0) | 27.00 (2.0) | <0.001a,b |
| SAND Global Score | 6.00 (4.0) | 2.00 (2.8) | 1.50 (3.0) | <0.001 a,b |
| PSP-tailored SAND Global Score | 8.00 (8.0) | 1.00 (4.8) | 1.00 (2.0) | <0.001a,b |
| PSP-rs | 43.50 (23.8) | NA | NA | NA |
Data are in median (Interquartile range, IQR), unless otherwise specified.
Significance threshold corrected for multiple comparisons = 0.002; significant differences are highlighted in bold.
Abbreviations:
a: PSP versus HC p < 0.001
b: PSP versus PD p < 0.001; HC: healthy controls; MMSE: Mini-Mental State Examination; NA: not applicable; PD: Parkinson’s disease; PSP: progressive supranuclear palsy; PSP-rs: progressive supranuclear palsy—rating scale; SAND: Screening for Aphasia in NeuroDegeneration.